Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 75 Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$27.79 (Fairly Valued). The stock has 6 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Applied BioCode ranks worse than 211864.19% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Applied BioCode's Debt-to-EBITDA or its related term are showing as below:
TPE:6598'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.11 Med: -0.4 Max: -0.01
Current: -0.64
During the past 13 years, the highest Debt-to-EBITDA Ratio of Applied BioCode was -0.01. The lowest was -1.11. And the median was -0.40.
TPE:6598's Debt-to-EBITDA is ranked worse than 100% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs TPE:6598: -0.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Applied BioCode Debt-to-EBITDA Related Terms
Applied BioCode Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Applied BioCode's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Applied BioCode (TPE:6598) has a Debt-to-EBITDA of 0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Applied BioCode. According to the industry distribution chart, Applied BioCode ranks #999999 out of 472 companies in the Medical Devices & Instruments industry.
Is Applied BioCode's Debt-to-EBITDA too high?
Applied BioCode's current Debt-to-EBITDA is 0.38. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Applied BioCode's value of 0.38 is 76.8% below this industry median. Based on the distribution chart, Applied BioCode ranks #999999 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #999999 out of 472 companies for Debt-to-EBITDA. This places Applied BioCode in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Applied BioCode's value of 0.38 is 76.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current Debt-to-EBITDA of 0.38 is 76.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Applied BioCode. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Debt-to-EBITDA is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$27.65 — trading 0.5% below its estimated fair value. The current Debt-to-EBITDA is 0.38 and 76.8% below the Medical Devices & Instruments industry median of 1.64. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$27.65 is trading 0.5% below its estimated GF Value™ of NT$27.79.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Debt-to-EBITDA: 0.38
GF Value™: NT$27.79 vs. price of NT$27.65 (0.5% below fair value)
Industry Position: 76.8% below the Medical Devices & Instruments median (#999999 of 472)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score
Get the complete analysis for TPE:6598
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
